Phase II study of vinblastine-CCNU, triazinate, and dactinomycin in advanced renal cell cancer.
A total of 133 patients with advanced or metastatic adenocarcinoma of the kidney were stratified according to performance status and time from initial diagnosis to recurrence and were then randomized to one of three different drug treatment arms or the crossover secondary treatment. The study drugs (combination vinblastine-CCNU and single-agent triazinate or dactinomycin) failed to provide any meaningful antitumor activity for these patients with advanced renal cell cancer.
D000230:Adenocarcinoma / Q000188:drug therapy*; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D002986:Clinical Trials as Topic; D003609:Dactinomycin / Q000008:administration & dosage; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy*; D008130:Lomustine / Q000008:administration & dosage; D011379:Prognosis; D014227:Triazines / Q000008:administration & dosage; D014747:Vinblastine / Q000008:administration & dosage
D000970:Antineoplastic Agents; D014227:Triazines; D003609:Dactinomycin; D014747:Vinblastine; D008130:Lomustine; C012071:triazinate